ALX Oncology (NASDAQ:ALXO) Trading Up 6.5%

ALX Oncology Holdings Inc. (NASDAQ:ALXO)’s stock price was up 6.5% during mid-day trading on Wednesday . The company traded as high as $15.67 and last traded at $15.43. Approximately 184,696 shares traded hands during trading, a decline of 55% from the average daily volume of 406,349 shares. The stock had previously closed at $14.49.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ALXO. Stifel Nicolaus restated a “hold” rating and set a $14.00 target price (up from $10.00) on shares of ALX Oncology in a research report on Friday, March 8th. Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a research report on Friday, April 12th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of ALX Oncology in a research report on Wednesday, April 10th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $18.83.

ALX Oncology Price Performance

The firm has a fifty day moving average of $13.50 and a two-hundred day moving average of $11.84. The company has a market capitalization of $800.39 million, a PE ratio of -3.86 and a beta of 1.58. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.05.

ALX Oncology (NASDAQ:ALXO) last released its quarterly earnings results on Thursday, March 7th. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.09). Research analysts anticipate that ALX Oncology Holdings Inc. will post -3.33 EPS for the current fiscal year.

Insider Buying and Selling at ALX Oncology

In other ALX Oncology news, insider Jaume Pons sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $11.15, for a total transaction of $223,000.00. Following the completion of the transaction, the insider now owns 628,359 shares of the company’s stock, valued at approximately $7,006,202.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Jason Lettmann bought 4,400 shares of the firm’s stock in a transaction dated Thursday, March 14th. The stock was purchased at an average price of $11.31 per share, with a total value of $49,764.00. Following the transaction, the chief executive officer now owns 171,620 shares of the company’s stock, valued at $1,941,022.20. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Jaume Pons sold 20,000 shares of the stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $11.15, for a total value of $223,000.00. Following the completion of the transaction, the insider now directly owns 628,359 shares of the company’s stock, valued at approximately $7,006,202.85. The disclosure for this sale can be found here. 50.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in ALX Oncology during the 4th quarter valued at approximately $28,000. Legal & General Group Plc increased its position in ALX Oncology by 42.6% during the 4th quarter. Legal & General Group Plc now owns 2,289 shares of the company’s stock valued at $34,000 after buying an additional 684 shares in the last quarter. Royal Bank of Canada increased its position in ALX Oncology by 226.6% during the 2nd quarter. Royal Bank of Canada now owns 4,001 shares of the company’s stock valued at $30,000 after buying an additional 2,776 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in ALX Oncology by 445.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,762 shares of the company’s stock valued at $86,000 after buying an additional 4,706 shares in the last quarter. Finally, Quantbot Technologies LP increased its position in ALX Oncology by 338.3% during the 1st quarter. Quantbot Technologies LP now owns 7,100 shares of the company’s stock valued at $119,000 after buying an additional 5,480 shares in the last quarter. Institutional investors own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.